Catch up on or relive the biggest headlines in healthcare of the past month.
From stem cell therapy breakthroughs to a national emergency declaration, August has been a month of peaks and valleys in the scope of healthcare.
The US Food and Drug Administration (FDA) alone made headlines. They approved a type 2 diabetes and obesity drug for cardiovascular risks associated with the condition. They partnered with their European peers. And, for the third time in 5 years, they rebuffed the advances of a potential Hepatitis B vaccine.
For all other major headlines you may have missed, we at MD Magazine compiled a list of the most popular stories of the month for some last-minute summer reading:
Botulinum neurotoxin serotype E, a potential alternative to BOTOX for frown line treatment, will be using Phase II trial data to set dosing for Phase II pain therapy indication studies in 2 models.
A new cost-effectiveness study has distinguished between the 6 oral DAA regimens recommended for treating chronic hepatitis C virus genotype 1 infection and the 4 regimens for treating genotype 4.
"With approximately 142 Americans dying every day, America is enduring a death toll equal to September 11th every three weeks."
Scientists in Denmark say they’re one step closer to developing a stem-cell therapy that could eventually allow patients with type 1 diabetes to be insulin independent again.
"The findings indicate that when a suicide attempt occurs in a unit, there is increased risk of another suicide attempt.”
Researchers re-evaluated previous work that showed progressive resistance training’s counteraction to brain atrophy in MS patients.
"There has been very little research done to date on asthma in the elderly, and we need to address whether current guidelines apply in this population or whether alternative strategies should be taken."
The researchers purposely contaminated tiles using a test solution with the specific C. difficile strains. The investigators allowed the tiles to dry for an hour and then were wiped or sprayed with one of the test products.
“This proves that vaccination in the indigenous population can have a very large impact on the disease burden."
A promising report from India appears to bolster the case that stem cell therapies might one day reverse the progression of multiple sclerosis, but experts say there remain many more questions than answers when it comes to the potential treatment option.